Answers are grounded in this paper and cite their sources.
Background: Respiratory viral infections such as COVID-19 and influenza represent significant public health threats, especially in vulnerable populations. Vitamin D has been promoted as an immunomodulatory agent, with previous studies suggesting an association between vitamin D levels and disease severity in respiratory infections. Additionally, genetic variations in the vitamin D receptor (VDR) may influence immune responses. Methods: This study investigates the relationship between vitamin D levels, VDR polymorphisms (rs1544410, rs731236, and rs7975232), and clinical severity in hospitalized patients with COVID-19 and influenza during the 2023–2024 winter season. Results: A total of 71 patients were included in this cross-sectional study. Vitamin D levels were significantly lower in severe COVID-19 cases (8.08 ng/mL, IQR: 4.79–15.7) compared to moderate forms (32.6 ng/mL, IQR: 13.0–38.6), as well as severe influenza cases (25.6 ng/mL, IQR: 18.9–34.5). Additionally, severe COVID-19 patients exhibited higher inflammatory markers (CRP, neutrophil count) and lower lymphocyte counts. However, no significant association was found between VDR polymorphisms and disease severity or vitamin D levels. Conclusions: These findings highlight the potential role of vitamin D in modulating disease severity in respiratory viral infections, while the influence of genetic polymorphisms remains uncertain. Further research is needed to determine whether vitamin D supplementation could improve clinical outcomes in these infections.
No takes yet. Share an insight, caveat, or question.
Sîrbu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: